Seeking Alpha

What’s behind Sarepta’s gene therapy deaths?

Three patient deaths linked to neuromuscular drugs developed by Sarepta Therapeutics (NASDAQ:SRPT) have drawn regulatory scrutiny on the viral vector used in the company’s gene therapy platform ...

Sarepta’s Elevidys safety concerns open major opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne therapy

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...
WSLS 10

Sarepta will resume gene therapy shipments after FDA review of recent patient death

WASHINGTON – Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a ...
WFMZ-TV

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

FILE - The name and logo of Sarepta Therapeutics is displayed on the company's headquarters, Monday, July 28, 2025, in Cambridge, Mass. WASHINGTON (AP) — The Food and Drug Administration said Friday ...

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Sarepta Therapeutics recently refinanced a significant portion of its debt, extending maturities and enhancing financial ...
STAT

A mother’s perspective on Sarepta’s gene therapy halt

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million.

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.